Beyond Weight Loss: The Cardiovascular Benefits of GLP-1 Receptor Agonists
Recent studies reveal that GLP-1 receptor agonists offer significant cardiovascular protection independent of weight loss, shifting the paradigm in preventative cardiology.
Latest Coverage
Beyond Weight Loss: The Cardiovascular Paradigm Shift of GLP-1 Receptor Agonists
Exploring the paradigm shift of GLP-1 receptor agonists from weight loss and diabetes management to potent cardiovascular risk reduction based on landmark clinical trials.
May 20, 2026 • 6 min readSemaglutide vs. Tirzepatide: What the Head-to-Head Data Actually Shows
A clinical comparison of semaglutide and tirzepatide based on SURMOUNT-5, STEP, and SURPASS data — efficacy, tolerability, and what the receptor pharmacology tells us about who responds best.
May 13, 2026 • 7 min readGLP-1s and Neuroprotection: Can Semaglutide Preserve Cognitive Function?
Emerging research indicates that GLP-1 receptor agonists may offer neuroprotective benefits, potentially transforming how we approach cognitive preservation and neurodegenerative diseases.
May 6, 2026 • 5 min readBeyond the Scale: The Cardiovascular and Metabolic Benefits of GLP-1 Receptor Agonists
Exploring the significant cardiovascular and metabolic benefits of GLP-1 receptor agonists beyond traditional weight loss and glycemic control.
May 6, 2026 • 6 min readGLP-1 Drugs Cut Fat, Not Muscle — But the Fine Print Matters
A new Cell Reports study demonstrates that proper protein and training protocols can preserve lean muscle mass during significant weight loss.
April 18, 2026 • 5 min readNavigating the Plateau: Science-Backed Strategies for Sustained Results
Hitting a weight-loss plateau on GLP-1 medications is common. Clinical science points to comprehensive lifestyle interventions to break through.
April 26, 2026 • 6 min read